U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H22F6O2
Molecular Weight 480.4421
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JNJ-40418677

SMILES

CC(C)C[C@H](C(O)=O)C1=CC(=CC(=C1)C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F

InChI

InChIKey=RQOWDDLKGBMJFX-QHCPKHFHSA-N
InChI=1S/C26H22F6O2/c1-15(2)11-23(24(33)34)20-13-18(16-3-7-21(8-4-16)25(27,28)29)12-19(14-20)17-5-9-22(10-6-17)26(30,31)32/h3-10,12-15,23H,11H2,1-2H3,(H,33,34)/t23-/m0/s1

HIDE SMILES / InChI
JNJ-40418677 is an inhibitor of gamma-secretase. JNJ-40418677 selectively reduced amyloid β 42 secretion in human neuroblastoma cells and rat primary neurones, but it did not inhibit Notch processing or formation of other amyloid precursor protein cleavage products. Oral treatment of non-transgenic mice with JNJ-40418677 resulted in an excellent brain penetration of the compound and a dose- and time-dependent decrease of brain amyloid β 42 levels. Chronic treatment of Tg2576 mice (a mouse model of Alzheimer's disease) with JNJ-40418677 reduced brain amyloid β levels, the area occupied by plaques and plaque number in a dose-dependent manner compared with transgenic vehicle-treated mice.

CNS Activity

Curator's Comment: JNJ-40418677 is CNS active in mice. No human data available.

Originator

Curator's Comment: # Johnson & Johnson Pharmaceutical Research and Development, Janssen Pharmaceutica

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
200.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease.
2011 May
Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches.
2014 Feb
Patents

Sample Use Guides

Chronic treatment of Tg2576 mice with 20-120 mg/kg/day JNJ-40418677 reduced brain amyloid β levels, the area occupied by plaques and plaque number in a dose-dependent manner compared with transgenic vehicle-treated mice.
Route of Administration: Oral
JNJ-40418677 selectively reduced amyloid β 42 secretion in human neuroblastoma cells (IC50= 200 nM) and rat primary neurones (IC50= 185 nM), JNJ-40418677 in micromolar range did not inhibit Notch processing or formation of other amyloid precursor protein cleavage products .
Name Type Language
JNJ-40418677
Common Name English
(1,1':3',1''-TERPHENYL)-5'-ACETIC ACID, .ALPHA.-(2-METHYLPROPYL)-4,4''-BIS(TRIFLUOROMETHYL)-, (.ALPHA.S)-
Systematic Name English
2-(S)-(3,5-BIS(4-(TRIFLUOROMETHYL)PHENYL)PHENYL)-4-METHYLPENTANOIC ACID
Systematic Name English
Code System Code Type Description
PUBCHEM
52939724
Created by admin on Sat Dec 16 19:09:59 GMT 2023 , Edited by admin on Sat Dec 16 19:09:59 GMT 2023
PRIMARY
CAS
1146594-87-7
Created by admin on Sat Dec 16 19:09:59 GMT 2023 , Edited by admin on Sat Dec 16 19:09:59 GMT 2023
PRIMARY
FDA UNII
Z1CWW31SGG
Created by admin on Sat Dec 16 19:09:59 GMT 2023 , Edited by admin on Sat Dec 16 19:09:59 GMT 2023
PRIMARY